J 2016

Divergent clonal selection dominates medulloblastoma at recurrence

MORRISSY, A. Sorana; Livia GARZIA; J.H. David SHIH; Scott ZUYDERDUYN; Xi HUANG et. al.

Základní údaje

Originální název

Divergent clonal selection dominates medulloblastoma at recurrence

Autoři

MORRISSY, A. Sorana; Livia GARZIA; J.H. David SHIH; Scott ZUYDERDUYN; Xi HUANG; Patryk SKOWRON; Marc REMKE; Florence M.G. CAVALLI; Vijay RAMASWAMY; Patricia E. LINDSAY; Salomeh JELVEH; Laura K. DONOVAN; Xin WANG; Betty LUU; Kory ZAYNE; Yisu LI; Chelsea MAYOH; Nina THIESSEN; Eloi MERCIER; Karen L. MUNGALL; Yusanne MA; Kane TSE; Thomas ZENG; Karey SHUMANSKY; Andrew J.L. ROTH; Sohrab SHAH; Hamza FAROOQ; Noriyuki KIJIMA; Borja L. HOLGADO; John J.Y. LEE; Stuart MATAN-LITHWICK; Jessica LIU; Stephen C. MACK; Alex MANNO; K.A. MICHEALRAJ; Carolina NOR; John PEACOCK; Lei QIN; Juri REIMAND; Adi ROLIDER; Yuan Y. THOMPSON; Xiaochong WU; Trevor PUGH; Adrian ALLY; Mikhail BILENKY; Yaron S.N. BUTTERFIELD; Rebecca CARLSEN; Young CHENG; Eric CHUAH; Richard D. CORBETT; Noreen DHALLA; An HE; Darlene LEE; Haiyan I. LI; William LONG; Michael MAYO; Patrick PLETTNER; Jenny Q. QIAN; Jacqueline E. SCHEIN; Angela TAM; Tina WONG; Inanc BIROL; Yongjun ZHAO; Claudia C. FARIA; José PIMENTEL; Sofia NUNES; Tarek SHALABY; Michael GROTZER; Ian F. POLLACK; Ronald L. HAMILTON; Xiao-Nan LI; Anne E. BENDEL; Daniel W. FULTS; Andrew W. WALTER; Toshihiro KUMABE; Teiji TOMINAGA; V. Peter COLLINS; Yoon-Jae CHO; Caitlin HOFFMAN; David LYDEN; Jeffrey H. WISOFF; James H. GARVIN JR; Duncan S. STEARNS; Luca MASSIMI; Ulrich SCHÜLLER; Jaroslav ŠTĚRBA; Karel ZITTERBART; Stephanie PUGET; Olivier AYRAULT; Sandra E. DUNN; Daniela P.C. TIRAPELLI; Carlos G. CARLOTTI; Helen WHEELER; Andrew R. HALLAHAN; Wendy INGRAM; Tobey J. MACDONALD; Jeffrey J. OLSON; Erwin G. Van MEIR; Ji-Yeoun LEE; Kyu-Chang WANG; Seung-Ki KIM; Byung-Kyu CHO; Torsten PIETSCH; Gudrun FLEISCHHACK; Stephan TIPPELT; Young Shin RA; Simon BAILEY; Janet C. LINDSEY; Steven C. CLIFFORD; Charles G. EBERHART; Michael K. COOPER; Roger J. PACKER; Maura MASSIMINO; Maria Luisa GARRE; Ute BARTELS; Uri TABORI; Cynthia E. HAWKINS; Peter DIRKS; Eric BOUFFET; James T. RUTKA; Robert J. WECHSLER-REYA; William A. WEISS; Lara S. COLLIER; Adam J. DUPUY; Andrey KORSHUNOV; David T.W. JONES; Marcel KOOL; Paul A. NORTHCOTT; Stefan M. PFISTER; David A. LARGAESPADA; Andrew J. MUNGALL; Richard A. MOORE; Nada JABADO; Gary D. BADER; Steven J.M. JONES; David MALKIN; Marco A. MARRA a Michael D. TAYLOR

Vydání

Nature, London, Nature Publishing Group, 2016, 0028-0836

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 40.137

Kód RIV

RIV/00216224:14110/16:00092045

Organizační jednotka

Lékařská fakulta

UT WoS

000368354800037

EID Scopus

2-s2.0-84955506668

Klíčová slova anglicky

SUBGROUP MEDULLOBLASTOMA; LYMPHOBLASTIC-LEUKEMIA; CANCER EVOLUTION; SEQUENCING DATA; GENOME; MUTATIONS; HETEROGENEITY; DYNAMICS; IMPACT; CELLS

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 1. 12. 2016 11:47, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The development of targeted anti-cancer therapies through the study of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity. We treated a transposon-driven, functional genomic mouse model of medulloblastoma with 'humanized' in vivo therapy (microneurosurgical tumour resection followed by multi-fractionated, image-guided radiotherapy). Genetic events in recurrent murine medulloblastoma exhibit a very poor overlap with those in matched murine diagnostic samples (<5%). Whole-genome sequencing of 33 pairs of human diagnostic and post-therapy medulloblastomas demonstrated substantial genetic divergence of the dominant clone after therapy (<12% diagnostic events were retained at recurrence). In both mice and humans, the dominant clone at recurrence arose through clonal selection of a pre-existing minor clone present at diagnosis. Targeted therapy is unlikely to be effective in the absence of the target, therefore our results offer a simple, proximal, and remediable explanation for the failure of prior clinical trials of targeted therapy.